146 related articles for article (PubMed ID: 9455457)
1. [The antiemetic action of tropisetron (Navoban) in the cytostatic treatment of neoplastic diseases].
Buiuc AI; Găleşanu MR
Rev Med Chir Soc Med Nat Iasi; 1996; 100(3-4):160-4. PubMed ID: 9455457
[TBL] [Abstract][Full Text] [Related]
2. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
Sorbe BG
Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
[TBL] [Abstract][Full Text] [Related]
3. [Effectiveness and tolerance of Navoban (5HT3-receptor antagonist tropisetron) in prevention of cytostatic drug-induced nausea and vomiting in patients with breast carcinomas and gynecological malignancies].
Regidor PA; Nelken B; Regidor M; Bier U; Oberhoff C; Schindler AE
Zentralbl Gynakol; 1996; 118(3):148-53. PubMed ID: 8900604
[TBL] [Abstract][Full Text] [Related]
4. Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents.
Bruntsch U; Drechsler S; Eggert J; Gosse H; Ukena D; Imhoff W; Faerber L
Semin Oncol; 1994 Oct; 21(5 Suppl 9):7-11. PubMed ID: 9113120
[TBL] [Abstract][Full Text] [Related]
5. A randomized, multicenter study comparing the efficacy and tolerability of tropisetron, a new 5-HT3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis.
Sorbe BG; Högberg T; Glimelius B; Schmidt M; Wernstedt L; Hansen O; Sörensen BT; Räisänen I; van Oosterom AT; de Bruijn KM
Cancer; 1994 Jan; 73(2):445-54. PubMed ID: 8293412
[TBL] [Abstract][Full Text] [Related]
6. A report comparing the use of tropisetron (Navoban), a 5-HT3 antagonist, with a standard antiemetic regimen of dexamethasone and metoclopramide in cisplatin-treated patients under conditions of severe emesis.
Madej G; Krzakowski M; Pawinski A; Lasota W; Rogowski W; Skoneczna I
Semin Oncol; 1994 Oct; 21(5 Suppl 9):3-6. PubMed ID: 9113119
[TBL] [Abstract][Full Text] [Related]
7. [Tropisetron hydrochloride in preventing and treating chemotherapy-induced nausea and vomiting: a phase II, randomized, multicenter, double-blinded, comparative clinical trial].
Zhang WD; Wang XW; Chen ZD; Qin FZ; Shu YQ; Pan LX; Zhang MH
Ai Zheng; 2007 Aug; 26(8):870-3. PubMed ID: 17697550
[TBL] [Abstract][Full Text] [Related]
8. Prevention of emesis by tropisetron (Navoban) in children receiving cytotoxic therapy for solid malignancies.
Otten J; Hachimi-Idrissi S; Balduck N; Maurus R
Semin Oncol; 1994 Oct; 21(5 Suppl 9):17-9. PubMed ID: 9113122
[TBL] [Abstract][Full Text] [Related]
9. Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban).
Morrow GR; Hickok JT; Rosenthal SN
Cancer; 1995 Aug; 76(3):343-57. PubMed ID: 8625113
[TBL] [Abstract][Full Text] [Related]
10. An open, randomized study to compare the efficacy and tolerability of tropisetron with that of a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis.
Sorbe B; Hallén C; Frankendal B
Cancer Chemother Pharmacol; 1994; 33(4):298-302. PubMed ID: 8281622
[TBL] [Abstract][Full Text] [Related]
11. Dose comparison of tropisetron (Navoban) 5 mg and 10 mg orally in the prophylaxis of dacarbazine-induced nausea and emesis.
Garbe C; Drechsler S; Fiedler H; Tilgen W; Landthaler M; Schroeder K; Kuehne KH; Faerber L
Semin Oncol; 1994 Oct; 21(5 Suppl 9):12-6. PubMed ID: 9113121
[TBL] [Abstract][Full Text] [Related]
12. Ondansetron and tropisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy.
Stiakaki E; Savvas S; Lydaki E; Bolonaki I; Kouvidi E; Dimitriou H; Kambourakis A; Kalmanti M
Pediatr Hematol Oncol; 1999; 16(2):101-8. PubMed ID: 10100270
[TBL] [Abstract][Full Text] [Related]
13. [The use of Navoban for managing nausea and vomiting during the aggressive chemotherapy of malignant neoplasms].
Seliuzhitskiĭ IV; Eliseev SN
Voen Med Zh; 1993 Oct; (10):35-6. PubMed ID: 8303850
[No Abstract] [Full Text] [Related]
14. Antiemetic control: 5-HT3 antagonists: review of clinical results, with particular emphasis on ondansetron.
Kidgell AE; Butcher ME; Brown GW
Cancer Treat Rev; 1990 Sep; 17(2-3):311-7. PubMed ID: 2176933
[No Abstract] [Full Text] [Related]
15. Is Navoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induced emesis? The French Navoban Study Group.
Marty M; Kleisbauer JP; Fournel P; Vergnenegre A; Carles P; Loria-Kanza Y; Simonetta C; de Bruijn KM
Anticancer Drugs; 1995 Feb; 6 Suppl 1():15-21. PubMed ID: 7749165
[TBL] [Abstract][Full Text] [Related]
16. Tropisetron in the prevention of acute and delayed nausea and vomiting over six courses of emetogenic chemotherapy.
Bleiberg H; Hulstaert F; Buyse M; De Keyser P
Anticancer Drugs; 1998 Oct; 9(9):773-7. PubMed ID: 9840722
[TBL] [Abstract][Full Text] [Related]
17. Optimal combination therapy with Navoban (tropisetron) in patients with incomplete control of chemotherapy-induced nausea and vomiting. The Belgian Navoban Group.
Van Belle SJ; Cocquyt VF; Bleiberg H; Canon JL; Buyse M; Hulstaert F; De Witte M; De Keyser P; Westelinck K
Anticancer Drugs; 1995 Feb; 6 Suppl 1():22-30. PubMed ID: 7749166
[TBL] [Abstract][Full Text] [Related]
18. The anti-emetic efficacy of tropisetron plus dexamethasone in patients treated with high-dose chemotherapy and stem cell transplantation.
Barbounis V; Koumakis G; Hatzichristou H; Vassilomanolakis M; Tsoussis S; Efremidis A
Support Care Cancer; 1999 Mar; 7(2):79-83. PubMed ID: 10089087
[TBL] [Abstract][Full Text] [Related]
19. Tropisetron (Navoban) in the prevention of chemotherapy-induced nausea and vomiting--the Nordic experience.
Sorbe B; Andersson H; Schmidt M; Söderberg M; Högberg T; Wernstedt L; Janson ET; Ehrnström B; Kjaer M; Havsteen H
Support Care Cancer; 1994 Nov; 2(6):393-9. PubMed ID: 7858934
[TBL] [Abstract][Full Text] [Related]
20. Navoban (tropisetron) alone and in combination with dexamethasone in the prevention of chemotherapy-induced nausea and vomiting: the Nordic experience. The Nordic Antiemetic Trial Group.
Sorbe BG; Högberg T; Glimelius B; Schmidt M; Wernstedt L; Andersson H; Hansen O; Sørensen BT; Räisänen I
Anticancer Drugs; 1995 Feb; 6 Suppl 1():31-6. PubMed ID: 7749168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
